Veru enters into common stock purchase agreement for up to $100 million with lincoln park capital

Miami, fl, may 03, 2023 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for sars-cov-2 and other viral ards-related diseases, today announced that it has entered into a common stock purchase agreement (agreement) for the purchase of up to $100 million with lincoln park capital fund (lpc), a chicago-based institutional investor.
VERU Ratings Summary
VERU Quant Ranking